Summary
72 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 30% a year over the last 3 years.
- It has raised its dividend 9 years in a row and pays out only 43% of profit.
- You pay 11.1 USD for 1 USD of yearly profit, little for its sector.
- Out of every 100 USD of revenue, 12 USD is left as net profit.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.1 USD for 1 USD of yearly profit. Over the last five years it was 18.3 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.9% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 1.0%. Earnings per share grew by 30% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 59 USD
- Research and development 4.8 USD
- Sales and administration 17 USD
- Taxes and other 8.1 USD
- Net profit 11 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 13.2 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 3.89%
- Paid out of profit
- 43%
- Raised in a row
- 9 years
You receive $0.86 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.